CGTX

Business Context and Reporting Period

Company: Cognition Therapeutics, Inc. (CGTX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative diseases of the central nervous system (CNS) and retina. The company has no products approved for commercial sale and has incurred significant losses since its inception in 2007. Its lead product candidate, zervimesine (CT1812), targets Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB) by preventing the binding of pathogenic protein oligomers to neuronal synapses.

Key Financial Metrics

Note: The company has no product revenue. Grant income is recognized as reimbursable costs are incurred.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $10.5 million (31%) from 2024 to 2025, primarily driven by a $6.2 million reduction in operating expenses and a $3.9 million increase in grant income.
• Operating Expenses: Total operating expenses declined to $47.8 million from $54.0 million. Research and Development (R&D) expenses decreased by $4.5 million due to reduced Phase 2 trial activities and lower personnel costs. General and Administrative (G&A) expenses decreased by $1.7 million, largely due to lower equity-based compensation.
• Liquidity Position: Cash and cash equivalents increased by $12.0 million to $37.0 million, supported by net proceeds of $27.9 million from a registered direct offering in August 2025 and $9.1 million from At-The-Market (ATM) sales.
• Capital Structure: The company terminated its previous ATM agreement with B. Riley in December 2025 and entered into a new $75 million ATM facility with Jefferies LLC. The Lincoln Park equity line financing expired in March 2026 with no draws in 2025.

Guidance, Outlook, and Risks

Management Commentary and Outlook

Management expects to incur significant and increasing expenses for the foreseeable future as it advances zervimesine through clinical development. The company believes its existing cash, cash equivalents, and available grant funds will be sufficient to fund operations through the second quarter of 2027. No specific financial guidance was provided.

Clinical Developments

• Alzheimer's Disease (AD): Enrollment completed in the Phase 2 START study (MCI/early AD) in December 2025; topline results expected after 18 months of treatment. The company plans to develop a Phase 3 program based on FDA feedback received in July 2025.
• Dementia with Lewy Bodies (DLB): Following positive Phase 2 SHIMMER results, the company plans to develop zervimesine for DLB psychosis. An Expanded Access Program (EAP) for DLB patients was fully enrolled in December 2025.
• Geographic Atrophy (GA): The Phase 2 MAGNIFY study for dry AMD was voluntarily concluded in January 2025 to conserve resources, despite showing a 29% reduction in lesion growth.

Key Risks and Contingencies

• Capital Needs: The company requires substantial additional capital to complete development and commercialization. Failure to raise funds could force curtailment of operations.
• Grant Dependency: Approximately $171 million in cumulative grants (primarily from the NIA) have funded clinical trials. Future funding is subject to political and regulatory changes, including potential reductions in indirect cost reimbursements.
• Regulatory Uncertainty: Success depends on FDA approval of zervimesine. The company faces risks related to clinical trial outcomes, regulatory feedback, and the novel nature of its mechanism of action.
• Manufacturing: The company relies entirely on third-party contract manufacturers for clinical and future commercial supply.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $37.0 million cash balance plus $35.7 million in available NIA funds to sustain operations through Q2 2027 without further dilution.
• Grant Sustainability: Assess the risk of reduced NIA funding due to the February 2025 policy announcement regarding indirect costs and the potential for future political shifts.
• Clinical Milestones: Monitor the timeline for topline results from the Phase 2 START study (AD) and the design of the proposed Phase 3 program.
• ATM Utilization: Track the utilization of the new $75 million ATM facility with Jefferies, as the previous facility was terminated.
• DLB Strategy: Evaluate the progress of the FDA discussions regarding the DLB psychosis indication and the enrollment status of the Expanded Access Program.